Frontline Tislelizumab Improves Survival in PD-L1+, Advanced Gastric/GEJ cancer

Tislelizumab plus chemotherapy may be a new first-line treatment option for patients with PD-L1-positive, advanced gastric or GEJ cancer.

Related Keywords

Germany ,Markush Moehler ,Johannes Gutenberg ,University Clinic In Mainz ,Johannes Gutenberg University Clinic ,